New research suggests GLP-1 drugs like Ozempic, Wegovy, Mounjaro may lower the risk of several obesity-related cancers, even matching surgery in preventive benefits
In adults with obesity but not diabetes, tirzepatide leads to significantly greater weight loss than semaglutide over 72 weeks, and nearly double the patients on tirzepatide meet the 25% weight-loss target. Medscape Medical News
A MUM has shared a downside of her epic weight loss transformation after being on Mounjaro for over two months. Scottish mum Kirsty took to TikTok after she shed almost a staggering 5 stone while on Mounjaro in a mere nine weeks. One Scottish mum took to TikTok to share the not so desirable side … Read more
INDIANAPOLIS, May 11, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP and GLP-1…
Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected anti-cancer benefits, particularly for obesity-related cancers. Studies indicate these medications could lower cancer risk independently of weight reduction, potentially by reducing inflammation and enhancing immune function. Further research is needed to fully understand their anti-cancer potential.
Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California on Thursday, May 8, 2025. (AP Photo/JoNel Aleccia) 2025-05-11T22:01:47Z People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who … Read more
Results are out from a key drug trial concerning one of the most important medical advances of the past decade – the arrival of safe and effective obesity treatments, in the form of weight loss jabs. The trial was a comparison of the first such medicine, Wegovy (also known as semaglutide, or Ozempic when used … Read more
Weight loss jabs, also known as GLP-1 receptor agonists, work by reducing food cravings
The common belief is that as GLP-1s become more popular, that will stimulate competition in generics and new drug development. This is all good, right? However, this has not always been true. This news article provides a detailed account of the history and exorbitant pricing of the drug Revlimid, a derivative of the controversial drug thalidomide, … Read more
